GSK 2793660Alternative Names: GSK-2793660
Latest Information Update: 20 May 2016
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchiectasis
Most Recent Events
- 19 Apr 2015 GlaxoSmithKline terminates phase I trial in Bronchiectasis (in volunteers) in United Kingdom (NCT02058407)
- 01 Jan 2014 Phase-I clinical trials in Bronchiectasis (in volunteers) in United Kingdom (PO, capsule; PO, liquid)